This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Daiichi Sankyo Co., Ltd.
Drug Names(s): DU-176b, Lixiana (Japan)
Description: Edoxaban is an oral, direct inhibitor of blood coagulation factor Xa.
Daiichi Sankyo and Daewoong Pharmaceutical
Daiichi Sankyo announced that its wholly owned subsidiary, Daiichi Sankyo Korea, and Daewoong Pharmaceutical have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, LIXIANA. No financial details were disclosed.
Daiichi Sankyo and Merck
In February 2016, Daiichi Sankyo announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group, has granted exclusive rights to Merck & Co, known as MSD outside the US and Canada to market the oral, once-daily anti-coagulant, LIXIANA (edoxaban), in 13 European countries: Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Iceland, Norway, Poland, Romania, Slovakia, Slovenia and Sweden.
The aforementioned 13 countries are subject to the marketing authorization of the oral, once-daily anti-coagulant edoxaban which was obtained from the European Commission last June. Sales will proceed as soon as MSD completes launch...See full deal structure in Biomedtracker
Partners: Daewoong Pharmaceutical Company Ltd. Merck & Co., Inc. Les Laboratoires Servier
Additional information available to subscribers only: